Block gene patents

THE FEB. 1 editorial “Protect biotech research, but not by patenting genes’’ is on target in stating that gene patents stifle innovation and cast a shadow on the best prospects to cure diseases. Gene patents, such as those Myriad Genetics holds on BRCA1 and 2, block advances in medicine and restrict laboratory medical professionals from doing what they are committed to do: engage in and implement research that will enhance the practice of medicine and patient care. Women’s options for diagnostic tests and second opinions are limited by these patents because other laboratories, and scientists are prohibited from performing some genetic tests for fear of patent infringement litigation. With no competition, patients are left with no choice but to pay the often high price for the test as controlled by the monopoly, i.e. the patent holder.